A Phase 1, Single Dose, Crossover, Relative Bioavailability Study of a Dolutegravir Dispersible Tablet as Compared to a Dolutegravir Pediatric Granule Formulation and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers(200401)
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2017
Price : $35 *
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 22 Jul 2015 Results presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.
- 28 Sep 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 14 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.